

DAFTAR PUSTAKA

- [1] “What Is Cancer?,” *National Cancer Institute*, 2015. <https://www.cancer.gov/about-cancer/understanding/what-is-cancer> (accessed Mar. 29, 2021).
- [2] “Global Cancer Observatory - South Eastern Asia,” *World Health Organization*, 2020. <https://gco.iarc.fr/today/data/factsheets/populations/920-south-eastern-asia-fact-sheets.pdf>.
- [3] “Global Cancer Observatory - Indonesia,” *World Health Organization*, 2020. <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf>.
- [4] American Cancer Society, “Breast Cancer (Fact and Figure 2019-2020),” 2020.
- [5] American Cancer Society, “Breast Cancer: Treating Breast Cancer,” *Am. Cancer Soc.*, pp. 1–120, 2019, [Online]. Available: <https://www.cancer.org/cancer/breast-cancer/treatment.html>.
- [6] “IBA to install Indonesia’s first proton therapy center,” © *IBA Worldwide 2021*, 2020. <https://www.iba-worldwide.com/content/iba-install-indonesia-s-first-proton-therapy-center> (accessed Dec. 30, 2021).
- [7] K. S. Corbin and R. W. Mutter, “Proton therapy for breast cancer: progress & pitfalls,” *Breast Cancer Manag.*, vol. 7, no. 1, p. BMT06, 2018, doi: 10.2217/bmt-2018-0001.
- [8] H. Suit *et al.*, “Proton vs carbon ion beams in the definitive radiation treatment of cancer patients,” *Radiother. Oncol.*, vol. 95, no. 1, pp. 3–22, 2010, doi: 10.1016/j.radonc.2010.01.015.
- [9] Y. Matsumoto, N. Fukumitsu, H. Ishikawa, K. Nakai, and H. Sakurai, “A critical review of radiation therapy: From particle beam therapy (proton, carbon, and bnct) to beyond,” *J. Pers. Med.*, vol. 11, no. 8, 2021, doi: 10.3390/jpm11080825.
- [10] J. B. Farr, J. B. Flanz, A. Gerbershagen, and M. F. Moyers, “New horizons in particle therapy systems,” *Med. Phys.*, vol. 45, no. 11, pp. e953–e983, 2018, doi: 10.1002/mp.13193.
- [11] J. Seco and F. Verhaegen, *Monte Carlo Techniques in Radiation Therapy*. 2021.
- [12] Z. Y. Yang *et al.*, “Inter-comparison of Dose Distributions Calculated by FLUKA, GEANT4, MCNP, and PHITS for Proton Therapy,” *EPJ Web Conf.*, vol. 153, pp. 1–8, 2017, doi: 10.1051/epjconf/201715304011.



- [13] H. PAULY, *Principles of radiobiology.*, vol. 2. Elsevier Inc., 1962.
- [14] D. Novianti, “ANALISIS DISTRIBUSI DOSIS RADIASI PADA TERAPI KANKER PAYUDARA DENGAN BORON NEUTRON CAPTURE THERAPY (BNCT) MENGGUNAKAN MCNP5,” Universitas Gadjah Mada, 2013.
- [15] M. Fadhilah, “OPTIMASI DOSIS RADIASI PADA KANKER PAYUDARA DENGAN METODE TERAPI PROTON MENGGUNAKAN PROGRAM PHITS (PARTICLE AND HEAVY ION TRANSPORT CODE SYSTEM),” Universitas Gadjah Mada, 2020.
- [16] A. Lühr *et al.*, “‘Radiobiology of Proton Therapy’: Results of an international expert workshop,” *Radiother. Oncol.*, vol. 128, no. 1, pp. 56–67, 2018, doi: 10.1016/j.radonc.2018.05.018.
- [17] J. Ödén, I. Toma-Dasu, K. Eriksson, A. M. Flejmer, and A. Dasu, “The influence of breathing motion and a variable relative biological effectiveness in proton therapy of left-sided breast cancer,” *Acta Oncol. (Madr.)*, vol. 56, no. 11, pp. 1428–1436, 2017, doi: 10.1080/0284186X.2017.1348625.
- [18] F. Tommasino *et al.*, “Model-based approach for quantitative estimates of skin, heart, and lung toxicity risk for left-side photon and proton irradiation after breast-conserving surgery,” *Acta Oncol. (Madr.)*, vol. 56, no. 5, pp. 730–736, 2017, doi: 10.1080/0284186X.2017.1299218.
- [19] H. Paganetti, *Proton Beam Therapy*. Boston, MA, USA: IOP Publishing, 2017.
- [20] “1 Introduction,” *J. ICRU*, vol. 7, no. 2, pp. 11–20, 2007, doi: 10.1093/jicru/ndm024.
- [21] S. M. MacDonald, T. F. DeLaney, and J. S. Loeffler, “Proton beam radiation therapy,” *Cancer Invest.*, vol. 24, no. 2, pp. 199–208, 2006, doi: 10.1080/07357900500524751.
- [22] U. Weber and G. Kraft, “Comparison of carbon ions versus protons,” *Cancer J.*, vol. 15, no. 4, pp. 325–332, 2009, doi: 10.1097/PPO.0b013e3181b01935.
- [23] M. Hu, L. Jiang, X. Cui, J. Zhang, and J. Yu, “Proton beam therapy for cancer in the era of precision medicine,” *J. Hematol. Oncol.*, vol. 11, no. 1, pp. 1–16, 2018, doi: 10.1186/s13045-018-0683-4.
- [24] D. Oh, “Proton therapy: the current status of the clinical evidences,” *Precis. Futur. Med.*, vol. 3, no. 3, pp. 91–102, 2019, doi: 10.23838/pfm.2019.00058.
- [25] A. Didi, H. Dekhissi, R. Sebihi, M. Krim, and R. M. Mohamed, “Calculate Primary and Secondary Dose in Proton Therapy Using 200 and 250 MeV Proton Beam Energy,” *Moscow Univ. Phys. Bull.*, vol. 74, no. 4, pp. 364–368, 2019, doi: 10.3103/S0027134919040064.
- [26] R. Mohan and D. Grosshans, “Proton therapy – Present and future,” *Adv.*



- Drug Deliv. Rev.*, vol. 109, pp. 26–44, 2017, doi: 10.1016/j.addr.2016.11.006.
- [27] I. I. C. on R. Protection, *Annals of the ICRP : Publication 103*, no. 0. 2003.
- [28] T. I. Marshall *et al.*, “Investigating the Implications of a Variable RBE on Proton Dose Fractionation Across a Clinical Pencil Beam Scanned Spread-Out Bragg Peak,” *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 95, no. 1, pp. 70–77, 2016, doi: 10.1016/j.ijrobp.2016.02.029.
- [29] S. Rana, K. Greco, E. J. Jebaseelan, and S. Jaafar, “Radiobiological and dosimetric impact of RayStation pencil beam and Monte Carlo algorithms on intensity - modulated proton therapy breast cancer plans,” no. February, pp. 36–46, 2019, doi: 10.1002/acm2.12676.
- [30] R. Mohan and D. Grosshans, “Proton therapy – Present and future,” *Adv. Drug Deliv. Rev.*, vol. 109, pp. 26–44, 2017, doi: <https://doi.org/10.1016/j.addr.2016.11.006>.
- [31] L. Schaub, S. Ben Harrabi, and J. Debus, “Particle therapy in the future of precision therapy,” *Br. J. Radiol.*, vol. 93, no. 1114, 2020, doi: 10.1259/bjr.20200183.
- [32] G. Klimpki *et al.*, “The impact of pencil beam scanning techniques on the effectiveness and efficiency of rescanning moving targets,” *Phys. Med. Biol.*, vol. 63, no. 14, 2018, doi: 10.1088/1361-6560/aacd27.
- [33] N. C. Estabrook, C. Cheng, D. Ph, and P. A. S. Johnstone, “Effect of Scanning Beam for Superficial Dose in Proton Therapy,” vol. 14, no. 5, 2015, doi: 10.7785/tcrt.2012.500435.
- [34] N. Hall and B. Rouge, “The physics of proton therapy,” *Phys. Med. Biol.*, vol. 60, no. 8, 2015, doi: 10.1088/0031-9155/60/8/R155.The.
- [35] R. Does, “How does radiation work to treat cancer?,” *Am. Cancer Soc.*, vol. 5–6, no. 01, pp. 3–9, 2018, [Online]. Available: <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/radiation/basics.html>.
- [36] H. Paganetti, *Proton Beam Therapy*. Bristol, UK: IOP Publishing, 2016.
- [37] “Regulation of the Cell Cycle (Interactive Tutorial),” *SCIENCEMUSICVIDEOS, L.L.C.* <https://sciencemusicvideos.com/ap-biology/module-12-the-cell-cycle/regulation-of-the-cell-cycle-interactive-tutorial/> (accessed Jun. 09, 2021).
- [38] R. A. W. Macrophages, “Immunomodulatory Effects of Radiotherapy,” no. 10 M, pp. 1–29, 2020, [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145302/pdf/molecules-25-01351.pdf>.
- [39] J. song Wang, H. juan Wang, and H. li Qian, “Biological effects of radiation



- on cancer cells,” *Mil. Med. Res.*, vol. 5, no. 1, pp. 1–10, 2018, doi: 10.1186/s40779-018-0167-4.
- [40] Proton Collaborative Group, “Phase II Study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Patients with Stage II/III, Loco-Regional, Non-Metastatic Breast Cancer Requiring Whole Breast or Chest Wall Irradiation with Lymph Node Irradiation,” pp. 1–71, 2014.
- [41] C. DerSarkissian, “Human Anatomy : Picture of the Breasts,” *WebMD, LLC*, 2019. <https://www.webmd.com/women/picture-of-the-breasts> (accessed Jun. 08, 2021).
- [42] H. J. Youn and W. Han, “A review of the epidemiology of breast cancer in Asia: Focus on risk factors,” *Asian Pacific J. Cancer Prev.*, vol. 21, no. 4, pp. 867–880, 2020, doi: 10.31557/APJCP.2020.21.4.867.
- [43] P. Lugo, D. Suquillo, F. Torres, F. Surre, and L. Trojman, “Critical Reviews in Oncology / Hematology Breast cancer , screening and diagnostic tools : All you need to know,” vol. 157, no. April 2020, 2021, doi: 10.1016/j.critrevonc.2020.103174.
- [44] “PET - CT Scans of the Breast.” http://www.aboutcancer.com/breast_pet_scans.htm (accessed May 02, 2021).
- [45] M. B. Amin *et al.*, “The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging,” *CA. Cancer J. Clin.*, 2017, doi: 10.3322/caac.21388.
- [46] S. Kalli, A. Semine, S. Cohen, S. P. Naber, S. S. Makim, and M. Bahl, “American joint committee on cancer’s staging system for breast cancer, eighth edition: What the radiologist needs to know,” *Radiographics*, vol. 38, no. 7, pp. 1921–1933, 2018, doi: 10.1148/rg.2018180056.
- [47] “Diagnosis Kanker Payudara,” *Modern Cancer Hospital Guangzhou, China All Rights Reserved*. <https://www.asiancancer.com/indonesian/cancer-diagnosis/breast-cancer-diagnosis/> (accessed May 02, 2021).
- [48] J. Koh and M. J. Kim, “Introduction of a new staging system of breast cancer for radiologists: An emphasis on the prognostic stage,” *Korean J. Radiol.*, vol. 20, no. 1, pp. 69–82, 2019, doi: 10.3348/kjr.2018.0231.
- [49] “What Is Lumpectomy?,” *Breastcancer.org*, 2015. https://www.breastcancer.org/treatment/surgery/lumpectomy/what_is (accessed Nov. 05, 2021).
- [50] J. Skowronek, “CT-Image Guided Brachytherapy,” *Theory Appl. CT Imaging Anal.*, no. April 2011, 2011, doi: 10.5772/14531.
- [51] M. Y. Park and S. E. Jung, “Patient dose management: Focus on practical



- actions,” *J. Korean Med. Sci.*, vol. 31, pp. S45–S54, 2016, doi: 10.3346/jkms.2016.31.S1.S45.
- [52] A. M. Reference and C. Phantoms, *ANNALS OF THE PUBLICATION 145 Adult Mesh-type Reference Computational Phantoms*, vol. 49, no. 3. 2020.
- [53] O. N. Vassiliev, *Monte Carlo Methods for Radiation Transport: Fundamentals and Advanced Topics*. 2016.
- [54] J. F. Briesmeister, “MCNP TM A General Monte Carlo N Particle Transport Code,” *Los Alamos Natl. Lab.*, no. March, p. 790, 2000.
- [55] S. Lechner, “DIPLOMARBEIT PHITS Modelling of an Experimental Setup for Proton Radiotherapy using an Anthropomorphic Phantom,” 2017.
- [56] “PHITS Introduction,” *Japan Atomic Energy Agency*, 2021. <https://phits.jaea.go.jp/> (accessed May 19, 2021).
- [57] JAEA, “PHITS Ver. 3.24 User’s Manual,” 2021.
- [58] Y. . Y. et all. C.H Kim, *ANNALS OF THE ICRP PUBLICATION 145 Adult Mesh-type Reference Computational Phantoms*, vol. 49, no. 3. 2020.
- [59] D. W. Mundy and T. Jevremovic, “Monte Carlo Assessment of Boron Neutron Capture Therapy for The Treatment of Breast Cancer,” no. 1, pp. 27–32, 2005.
- [60] L. Energy, “2 Radiation Biology Considerations,” *J. ICRU*, vol. 7, no. 2, pp. 21–28, 2007, doi: 10.1093/jicru/ndm025.
- [61] S. Helmbrecht, M. Baumann, W. Enghardt, F. Fiedler, M. Krause, and A. Lühr, “Design and implementation of a robust and cost-effective double-scattering system at a horizontal proton beamline,” *J. Instrum.*, vol. 11, no. 11, 2016, doi: 10.1088/1748-0221/11/11/T11001.
- [62] A. Kern, C. Bäumer, K. Kröninger, J. Wulff, and B. Timmermann, “Impact of air gap, range shifter, and delivery technique on skin dose in proton therapy,” *Med. Phys.*, vol. 48, no. 2, pp. 831–840, 2021, doi: 10.1002/mp.14626.
- [63] L. Coia, “TOLERANCE OF NORMAL TISSUE TO THERAPEUTIC IRRADIATION,” *Curr. Pract.*, vol. 21, pp. 109–122, 1991.
- [64] M. T. Milano, L. S. Constine, and P. Okunieff, “Normal Tissue Tolerance Dose Metrics for Radiation Therapy of Major Organs,” *Semin. Radiat. Oncol.*, vol. 17, no. 2, pp. 131–140, 2007, doi: 10.1016/j.semradonc.2006.11.009.

